Find Nephrology Clinical Drug Pipeline Developments & Deals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Budesonide

            Therapeutic Area: Nephrology Product Name: Nefecon

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            Following IND approval by the NMPA in December of 2019 and subsequent approval by Human Genetic Resources Administration of China (HGRAC), the first patient in China has now been randomized in the Phase 3 NefIgArd trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GFB-887

            Therapeutic Area: Nephrology Product Name: GFB-887

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            TRACTION-2 is a multicenter, double-blind, randomized, placebo controlled Phase 2 trial evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GFB-887 in approximately 125 patients with FSGS or DN.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Alfacalcidol

            Therapeutic Area: Nephrology Product Name: One-Alpha

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh

            Deal Size: $355.0 million Upfront Cash: Undisclosed

            Deal Type: Divestment August 31, 2020

            Details:

            The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©, Locoid©, Pimafucin©, and Zineryt©.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Nephrology Product Name: Farxiga

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 30, 2020

            Details:

            Results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s Farxiga on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo in CKD patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Nephrology Product Name: Farxiga

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            Farxiga shows significant benefit across all primary and secondary endpoints in patients with chronic kidney disease with and without type-2 diabetes .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vadadustat

            Therapeutic Area: Nephrology Product Name: Vafseo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 26, 2020

            Details:

            Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is now commercially available in Japan as a treatment for anemia due to chronic kidney disease (CKD) under the trade name VAFSEO™.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Veverimer

            Therapeutic Area: Nephrology Product Name: TRC101

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            Details:

            Tricida has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for veverimer on August 21, 2020. The NDA was reviewed under the Accelerated Approval Program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atrasentan Hydrochloride

            Therapeutic Area: Nephrology Product Name: ABT-627

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: EcoR1 Capital

            Deal Size: $106.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement August 18, 2020

            Details:

            Net proceeds will support company's planned phase 2 and phase 3 trials of atrasentan, an investigational selective endothelin receptor antagonist, in development for the treatment of IgA nephropathy and other primary glomerular diseases including other clinical activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DM199

            Therapeutic Area: Nephrology Product Name: DM199

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Guggenheim Securities, LLC

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering August 06, 2020

            Details:

            Net proceeds to be used in continuing clinical and product development activities, including the addition of a new cohort III to its REDUX study to be comprised of Type II diabetes mellitus patients with CKD, hypertension and albuminuria, and general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Propagermanium

            Therapeutic Area: Nephrology Product Name: DMX-200

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 29, 2020

            Details:

            Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients, 86% of patients demonstrated a reduction of proteinuria with DMX-200 versus placebo.

            PharmaCompass